Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study
Annals of Rheumatic Diseases Oct 04, 2017
Cohen S, et al. - The objective of this study is to report outcomes from a phase III study comparing the effectiveness, safety and immunogenicity between ABP 501 and adalimumab. The outcomes of this study exhibit that ABP 501 is similar to adalimumab in clinical efficacy, safety and immunogenicity in patients with moderate to severe rheumatoid arthritis (RA).
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
